Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy (Q38163046)

30 August 2017

title

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy (English)

1 reference

30 August 2017

0 references

M S Freedman

1

1 reference

30 August 2017

publication date

15 November 2013

1 reference

European Journal of Neurology

30 August 2017

published in

1 reference

30 August 2017

volume

21

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

377-87, e18-20

1 reference

Multiple sclerosis: current treatment algorithms.

30 August 2017

cites work

1 reference

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

21 January 2018

1 reference

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients

21 January 2018

1 reference

Fingolimod for multiple sclerosis

21 January 2018

1 reference

Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command

21 January 2018

1 reference

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

21 January 2018

1 reference

Axonal Transection in the Lesions of Multiple Sclerosis

21 January 2018

1 reference

Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence

21 January 2018

1 reference

Treatment optimization in multiple sclerosis: report of an international consensus meeting

21 January 2018

1 reference

21 January 2018

1 reference

Predicting responders to therapies for multiple sclerosis

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

21 January 2018

1 reference

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

21 January 2018

1 reference

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

21 January 2018

1 reference

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland

21 January 2018

1 reference

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

21 January 2018

1 reference

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

21 January 2018

1 reference

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

Immunogenicity of biopharmaceuticals

21 January 2018

1 reference

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

21 January 2018

1 reference

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod

21 January 2018

1 reference

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

21 January 2018

1 reference

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

21 January 2018

1 reference

Primary central nervous system lymphoma in a patient treated with natalizumab

21 January 2018

1 reference

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

21 January 2018

1 reference

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment

21 January 2018

1 reference

Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

21 January 2018

1 reference

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

21 January 2018

1 reference

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

Primary central nervous system lymphoma in a patient treated with Natalizumab

21 January 2018

1 reference

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ENE.12299

1 reference

30 August 2017

1 reference